A variability in response of osteoclasts to zoledronic acid is mediated by smoking associated modifcation in the DNA methylome

A variability in response of osteoclasts to zoledronic acid is mediated by smoking associated modifcation in the DNA methylome

Qihua TanAnaïs Marie Julie MøllerChuan QiuJonna Skov MadsenHui ShenTroels BechmannJean-Marie DelaisseBjarne Winther KristensenHong-Wen DengDavid Karasik & Kent Søe

A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome | Clinical Epigenetics | Full Text (biomedcentral.com)

Background Clinical trials have shown zoledronic acid as a potent bisphosphonate in preventing bone loss, but with varying potency between patients. Human osteoclasts ex vivo reportedly displayed a variable sensitivity to zoledronic acid>200-fold, determined by the half-maximal inhibitory concentration (IC50), with cigarette smoking as one of the reported contributors to this variation. To reveal the molecular basis of the smoking-mediated variation on treatment sensitivity, we performed a DNA methylome profling on whole blood cells from 34 healthy female blood donors. Multiple regression models were ftted to associate DNA methylation with ex vivo determined IC50 values, smoking,
and their interaction adjusting for age and cell compositions.
Results We identifed 59 CpGs displaying genome-wide signifcance (p<1e−08) with a false discovery rate
(FDR)<0.05 for the smoking-dependent association with IC50. Among them, 3 CpGs have p<1e−08 and
FDR<2e−03. By comparing with genome-wide association studies, 15 signifcant CpGs were locally enriched (within<50,000 bp) by SNPs associated with bone and body size measures. Furthermore, through a replication analysis using data from a published multi-omics association study on bone mineral density (BMD), we could validate that 29 out of the 59 CpGs were in close vicinity of genomic sites signifcantly associated with BMD. Gene Ontology (GO) analysis on genes linked to the 59 CpGs displaying smoking-dependent association with IC50, detected 18 signifcant GO terms including cation:cation antiporter activity, extracellular matrix conferring tensile strength, ligand–gated ion channel activity, etc.
Conclusions Our results suggest that smoking mediates individual sensitivity to zoledronic acid treatment through epigenetic regulation. Our novel fndings could have important clinical implications since DNA methylation analysis may enable personalized zoledronic acid treatment.

Recent News

The Special Issue on “The Role of Nutrition in Osteoarthritis Development” of Nutrients (ISSN 2072-6643) (impact factor of 6.706), is now open for submission.  For more information, please check the link to the...
“BioGeMT Project – Recruitment of the Team which will support the ERA Chair holderThe ERA Chair Team for this project will involve the recruitment of:(i) Researchers to perform Bioinformatics research, data analysis,...
Iryna Khrystoforova has just finished her PhD at Bar-Ilan University, Azrieli Faculty of Medicine under supervision of Prof. Karasik, Genetics of musculoskeletal diseases lab. Currently she is a Postdoc at...
Ines Alves is the founder and president of ANDO Portugal, the Skeletal Dysplasia National Association as well as the representative of the European Patient Advocacy groups (ePAG) and many other...
Artemis GKITAKOU, Research Assistant of Erasmus MC with main interests in life style and bone health.. Here, you can find her experience from participating in the GEMSTONE Mobility project: My...
4 postdoc positions to join the ERA-Net project IMMOSCAN and work on the role of immune osteoclasts in cancer – implications for therapy.